lranian journal of Clinical Infectious Diseases | |
Phase I Safety and Clinical Activity Study of Thymoquinone in Patients with Advanced Refractory Malignant Disease. | |
Ali M. Al-Amri, MD2  Abdullah O. Bamosa MBBS, PHD1  | |
[1] Department of Physiology, College of Medicine, King Faisal University, Dammam, Saudi Arabia.;Department of Internal Medicine/Oncology, College of Medicine, King Faisal University, King Fahd Hospital of the University, Al-Khobar, Eastern Province, Kingdom of Saudi Arabia. | |
关键词: Thymoquinone; Cancer; Toxicity; | |
DOI : 10.17795/semj20501 | |
学科分类:基础医学 | |
来源: Shiraz University of Medical Sciences | |
【 摘 要 】
Purpose::ThisphaseIstudywasconductedtodeterminethegeneraltoxicitiesofthymoquinoneinhumans,aswellasanyanti-cancereffectsthatthedrugmayhaveinpatientswithadvancedcancerforwhichtherewerenostandardcurativeorpalliativemeasures.Patientsandmethods::Adultpatientswithsolidtumorsorhematologicalmalignancieswhohadfailedorrelapsedfromstandardtherapywereincludedinthisstudy.Patientswhowereatleast18yearsofagewithanEasterncooperativeoncologygroupperformancestatus(ECOG)of≤2receivedthymoquinoneorallyatastartingdoselevelof3,7,or10mg/kg/day.DoseescalationproceededaccordingtoamodifiedFibonaccidesign.Results::All21patientsreceivedatleastoneweekoftreatment,withamedianof3.71weeks(range1weekto20weeks).Nosideeffectswerereportedandthemaximumtolerateddose(MDT)wasnotidentified.Noanti-cancereffectswereobserved.Conclusion::Onthebasisofthisstudy,thymoquinonewaswelltoleratedatadoserangingfrom75mg/dayto2600mg/day.Neithertoxicitiesnortherapeuticresponseswerereported.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912090831942ZK.pdf | 77KB | download |